# The Center for Therapeutic Targeting of EWS-oncoproteins

> **NIH NIH U54** · DANA-FARBER CANCER INST · 2022 · $505,427

## Abstract

PROJECT SUMMARY: Overall
This section is unchanged from the U54 CA231637 parent award
The primary scientific focus of this Center is to understand the molecular underpinnings of EWS-ETS driven
Ewing sarcoma and to investigate novel treatments and therapeutic mechanisms to improve outcomes for
pediatric patients with this aggressive disease. Translation of molecular understanding of sarcoma
pathophysiology into effective new drugs in the clinic is a complex, risky proposition that requires the
coordinated efforts of a talented team of individuals with complementary skills. This group brings expertise in
Ewing sarcoma biology and the EWS-ETS oncoproteins, epigenetics and transcription, structural biology,
computational biology, chemical biology and drug development, mouse models, preclinical experimental
therapeutics, and clinical trials development. A Center mechanism is essential to the success of this proposal.
No one institution nor individual can bring mastery of the diversity of approaches, technologies, and scientific
domains needed to achieve the goals of this proposal. We have elected to focus on understanding the
fundamental inner workings of Ewing sarcoma from its transcriptional circuits, to the direct protein interactions
with EWS-FLI1, to the direct and immediate effects of EWS-FLI1 degradation. Moreover, a strong emphasis
of this proposal is on target identification and preclinical validation, critical steps in the process of bringing
forward therapies with optimal chances for success in the clinic. The team that is assembled has all of the
component pieces needed for success. Our Center includes outstanding basic cancer biologists, chemists,
computational biologists, and translational researchers, and five pediatric oncologists. Thus, the proposed
Center can catalyze basic discovery and clinical translation by leveraging basic and clinical research talent
within the Center and our strong ties to outside academic and industrial partners.

## Key facts

- **NIH application ID:** 10671815
- **Project number:** 3U54CA231637-01S2
- **Recipient organization:** DANA-FARBER CANCER INST
- **Principal Investigator:** SCOTT A ARMSTRONG
- **Activity code:** U54 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $505,427
- **Award type:** 3
- **Project period:** 2022-09-07 → 2024-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10671815

## Citation

> US National Institutes of Health, RePORTER application 10671815, The Center for Therapeutic Targeting of EWS-oncoproteins (3U54CA231637-01S2). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10671815. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*